4.08
+0.08
(2.00%)
May 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 3.80 - 4.08 |
| 52 week | 2.05 - 5.90 |
| Open | 4.00 |
| Vol / Avg. | 340,599.00/866,906.00 |
| Mkt cap | 14.45M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 354.09M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jul 17, 2013
Summit Corporation PLC Annual General Meeting
|
|
Key stats and ratios
| Q3 (Jul '12) | 2012 | |
| Net profit margin | -219.92% | -152.63% |
| Operating margin | -234.91% | -170.09% |
| EBITD margin | - | -158.19% |
| Return on average assets | -95.04% | -59.95% |
| Return on average equity | -123.81% | -88.56% |
| Employees | 31 | - |
| Carbon Disclosure Rating | - | - |
Address
91 Milton Park
ABINGDON, ENG OX14 4RY
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-443999 (Fax)
ABINGDON, ENG OX14 4RY
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-443999 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Summit Corporation plc (Summit) is a drug discovery company. The Company is engaged in developing drug candidates to treat areas of unmet medical need. The Company focuses on advancing three drug programmes targeting Duchenne Muscular Dystrophy, C. difficile infection and Alzheimer�s disease and other tauopathies. The Company�s programmes include SMT 19969, SMT C1100, SMT C2100, SMT 14224, SMT 15000, SMT D001 (Sialorrhoea), SMT D002 (Seborrhoea), Glaucoma / AMD and Tuberculosis Programme. Summit also has Seglin technology, a chemistry based drug discovery platform. The Company�s subsidiaries include Summit (Oxford) Limited, Summit (Wales) Limited, Summit (Cambridge) Limited, Summit Discovery 1 Limited and Summit Corporation Employee Benefit Trust Company Limited.
Officers and directors
| Glyn Edwards | Chief Executive Officer, Executive Director | |
| Raymond J. Spencer | Chief Financial Officer, Company Secretary | |
| Barry Price Ph.D. | Non-Executive Chairman of the Board | |
| Frank Murdoch Armstrong | Non-Executive Director | |
| Jim Mellon | Non-Executive Director |